Immunohistochemically, the EBV-positive component of the tumor was diffusely positive for C-MYC and negative for HER2, while the EBV-negative part was positive for HER2 and negative for C-MYC (Fig. 3g–l). This evidence concerns the gene ERBB2 and neoplasm.